• November 6, 2026



Choice Institutional Equities is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated November 05, 2026.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Wheaton Precious Metals revenue jumps 62% as record year-to-date performance builds

What Is Real Property?

Related Posts

Taxation of equities: The FIFO strategy smart investors use to cut capital gains tax and…

By  

Why these 2 ASX ETFs could be the best dividend funds for retirees

By  

3 Best ETFs for Rising Interest Rates

By  

Mahindra Manulife launches equity long-short fund

By